title: Hemolytic anemia associated with antineoplastic agents.
abstract: Hemolytic anemia is an uncommon, but important, complication following the administration of antineoplastic agents. Three types of hemolytic anemia have been reported: microangiopathic hemolytic anemia, immune hemolytic anemia, and oxidative hemolysis. Physicians should be alert to the possibility of this adverse effect in any patient who has a sudden or unexplained drop in hemoglobin concentration while undergoing cancer chemotherapy. If the hemolytic anemia is not recognized and allowed to continue, the consequences may prove to be fatal.
authors.forename: D C
authors.initials: DC
authors.lastname: Doll
authors.forename: R B
authors.initials: RB
authors.lastname: Weiss
mesh_terms: D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D003070:Coformycin / Q000009:adverse effects / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000009:adverse effects; D004611:Ellipticines / Q000009:adverse effects; D006801:Humans; D007105:Immune Complex Diseases / Q000139:chemically induced; D007668:Kidney / Q000098:blood supply; D007674:Kidney Diseases / Q000139:chemically induced; D008558:Melphalan / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D008937:Mitomycins / Q000009:adverse effects; D009369:Neoplasms / Q000097:blood / Q000150:complications; D010084:Oxidation-Reduction; D015649:Pentostatin; D011720:Pyrazoles / Q000009:adverse effects; D013713:Teniposide / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D004611:Ellipticines; D008937:Mitomycins; D011720:Pyrazoles; D003070:Coformycin; C027767:elliptinium; D015649:Pentostatin; D004317:Doxorubicin; D013713:Teniposide; C000971:2,3-dihydro-1H-imidazo(1,2-b)pyrazole; D002945:Cisplatin; D008558:Melphalan; D008727:Methotrexate